Abbott Laboratories
NYSE:ABT
Abbott Laboratories
Net Income (Common)
Abbott Laboratories
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Abbott Laboratories
NYSE:ABT
|
Net Income (Common)
$13.4B
|
CAGR 3-Years
24%
|
CAGR 5-Years
29%
|
CAGR 10-Years
19%
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Net Income (Common)
$1.7B
|
CAGR 3-Years
1%
|
CAGR 5-Years
18%
|
CAGR 10-Years
4%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Net Income (Common)
$1.9B
|
CAGR 3-Years
23%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Net Income (Common)
$4.2B
|
CAGR 3-Years
41%
|
CAGR 5-Years
32%
|
CAGR 10-Years
18%
|
|
|
Stryker Corp
NYSE:SYK
|
Net Income (Common)
$3B
|
CAGR 3-Years
14%
|
CAGR 5-Years
8%
|
CAGR 10-Years
19%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Net Income (Common)
$2.3B
|
CAGR 3-Years
11%
|
CAGR 5-Years
11%
|
CAGR 10-Years
19%
|
|
Abbott Laboratories
Glance View
Nestled into the landscape of global healthcare, Abbott Laboratories emerges as a stalwart that champions scientific innovation and broad accessibility. Established in 1888 by Dr. Wallace Calvin Abbott, the company evolved from a modest medicinal compounding business into a diversified healthcare conglomerate. Today, Abbott's reach extends across more than 160 countries, where it dedicates itself to advancing human health through a wide array of products, including diagnostics, medical devices, nutritionals, and branded generic medicines. This diverse portfolio enables Abbott to remain resilient amid varying market conditions, ensuring its stability and growth are less susceptible to the cyclical nature of any single healthcare segment. Central to Abbott's operations is its prowess in diagnostics and medical devices, both sectors contributing significantly to the company's bottom line. Diagnostics equip healthcare providers with advanced tools to detect diseases early, tailoring treatments to improve patient outcomes—a demand ballooning in tandem with global health awareness. Moreover, Abbott’s innovative medical devices, from cardiovascular to neuromodulation technologies, address some of the most pressing health challenges. Meanwhile, the company’s nutrition products, such as infant formulas and dietary supplements, tap into a burgeoning global appetite for health-conscious living. Each of these ventures feeds into Abbott's strategy of sustaining growth through constant innovation, strategic international expansion, and responsiveness to healthcare trends and needs worldwide. It's this blend of diversification and specialization that keeps the company at the forefront of the healthcare arena.
See Also
What is Abbott Laboratories's Net Income (Common)?
Net Income (Common)
13.4B
USD
Based on the financial report for Dec 31, 2024, Abbott Laboratories's Net Income (Common) amounts to 13.4B USD.
What is Abbott Laboratories's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
19%
Over the last year, the Net Income (Common) growth was 134%. The average annual Net Income (Common) growth rates for Abbott Laboratories have been 24% over the past three years , 29% over the past five years , and 19% over the past ten years .
You don't have any saved screeners yet